Syndax Pharmaceuticals Company Insiders
SNDX Stock | USD 16.51 0.01 0.06% |
Syndax Pharmaceuticals employs about 184 people. The company is managed by 18 executives with a total tenure of roughly 430 years, averaging almost 23.0 years of service per executive, having 10.22 employees per reported executive. Break down of Syndax Pharmaceuticals' management performance can provide insight into the company performance.
Syndax |
Syndax Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Syndax Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Syndax will maintain a workforce of slightly above 180 employees by December 2024.Syndax Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.4867) % which means that it has lost $0.4867 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8188) %, meaning that it created substantial loss on money invested by shareholders. Syndax Pharmaceuticals' management efficiency ratios could be used to measure how well Syndax Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.36 in 2024. Return On Capital Employed is likely to drop to -0.44 in 2024. At this time, Syndax Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 33.6 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 646 K in 2024.Common Stock Shares Outstanding is likely to drop to about 38.8 M in 2024. Net Loss is likely to rise to about (127.7 M) in 2024
Syndax Pharmaceuticals Workforce Comparison
Syndax Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 3,969. Syndax Pharmaceuticals holds roughly 184 in number of employees claiming about 5% of equities under Health Care industry.
Syndax Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Syndax Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Syndax Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Syndax Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2023-09-01 | 0.6 | 6 | 10 | 189,572 | 377,420 |
2023-06-01 | 0.5556 | 5 | 9 | 408,565 | 317,707 |
2023-03-01 | 1.75 | 21 | 12 | 1,056,736 | 280,831 |
2022-12-01 | 1.3 | 13 | 10 | 295,833 | 111,260 |
2022-09-01 | 0.6667 | 18 | 27 | 676,947 | 980,066 |
2022-06-01 | 1.0 | 6 | 6 | 380,551 | 110,429 |
2022-03-01 | 8.0 | 16 | 2 | 924,444 | 2,380 |
2021-12-01 | 0.5161 | 16 | 31 | 317,705 | 684,111 |
2021-09-01 | 0.7143 | 10 | 14 | 242,947 | 292,718 |
2021-06-01 | 1.25 | 5 | 4 | 28,576 | 27,218 |
2021-03-01 | 2.375 | 19 | 8 | 865,043 | 120,794 |
2020-12-01 | 0.5455 | 6 | 11 | 225,376 | 363,526 |
2020-09-01 | 3.0 | 3 | 1 | 8,830 | 215,000 |
2018-06-01 | 2.2 | 11 | 5 | 2,105,500 | 2,015,000 |
2017-06-01 | 7.5 | 15 | 2 | 105,732 | 5,732 |
2017-03-01 | 8.0 | 8 | 1 | 671,100 | 125,000 |
2016-03-01 | 0.3333 | 17 | 51 | 9,781,100 | 13,624,856 |
Syndax Pharmaceuticals Notable Stakeholders
A Syndax Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Syndax Pharmaceuticals often face trade-offs trying to please all of them. Syndax Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Syndax Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Neil MD | President Development | Profile | |
Luke JD | General VP | Profile | |
Luke Albrecht | General VP | Profile | |
Briggs MD | Head Pres | Profile | |
Steven Closter | Chief Officer | Profile | |
Michael MBA | CEO Director | Profile | |
Steve Sabus | Chief Officer | Profile | |
Joseph MD | Member Officer | Profile | |
Ronald Evans | Advisor CoFounder | Profile | |
Sharon Klahre | Vice Communications | Profile | |
Peter BSc | CoFounder Officer | Profile | |
Anjali Ganguli | Chief Officer | Profile | |
Alexander Nolte | VP Officer | Profile | |
Kevin McManus | Chief Officer | Profile | |
Michael Downes | CoFounder | Profile | |
Richard Heyman | CoFounder | Profile | |
Catherine MD | Chief Officer | Profile | |
Keith CPA | Chief Officer | Profile |
About Syndax Pharmaceuticals Management Performance
The success or failure of an entity such as Syndax Pharmaceuticals often depends on how effective the management is. Syndax Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Syndax management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Syndax management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.34) | (0.36) | |
Return On Capital Employed | (0.41) | (0.44) | |
Return On Assets | (0.34) | (0.36) | |
Return On Equity | (0.38) | (0.40) |
Please note, the imprecision that can be found in Syndax Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Syndax Pharmaceuticals. Check Syndax Pharmaceuticals' Beneish M Score to see the likelihood of Syndax Pharmaceuticals' management manipulating its earnings.
Syndax Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Syndax Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Syndax Pharmaceuticals within its industry.Syndax Pharmaceuticals Manpower Efficiency
Return on Syndax Pharmaceuticals Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.1M | |
Net Loss Per Executive | 11.6M | |
Working Capital Per Employee | 2.8M | |
Working Capital Per Executive | 29M |
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.